Randomized phase IV trial comparing efficacy and tolerability of temsirolimus with and without an elevated starting dose in patients with relapsed, refractory mantle cell lymphoma.

被引：1
|
作者：
Bair, A.
Hess, G.
Boni, J.
Offner, F.
机构：
[1] Pfizer Oncol, San Diego, CA USA
[2] Klinikum Johannes Gutenberg Univ, Med Klin & Poliklin 3, Mainz, Germany
[3] Pfizer Inc, Collegeville, PA USA
[4] Univ Ziekenhuis Gent, Ghent, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps222
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS222
引用
收藏
页数：1
相关论文
共 50 条
  • [41] PHASE 3 STUDY OF PATIENTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA: COMPARISON OF TREATMENT WITH TEMSIROLIMUS vs INVESTIGATOR'S CHOICE THERAPY
    Verhoef, E. G.
    He, G.
    Romaguera, J.
    Herbrecht, R.
    Crump, M.
    Strahs, A.
    Hanushevsky, O.
    Binlich, F.
    Hewes, B.
    Coiffier, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 174 - 174
  • [42] Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
    Dreyling, Martin
    Jurczak, Wojciech
    Jerkeman, Mats
    Silva, Rodrigo Santucci
    Rusconi, Chiara
    Trneny, Marek
    Offner, Fritz
    Caballero, Dolores
    Joao, Cristina
    Witzens-Harig, Mathias
    Hess, Georg
    Bence-Bruckler, Isabelle
    Cho, Seok-Goo
    Bothos, John
    Goldberg, Jenna D.
    Enny, Christopher
    Traina, Shana
    Balasubramanian, Sriram
    Bandyopadhyay, Nibedita
    Sun, Steven
    Vermeulen, Jessica
    Rizo, Aleksandra
    Rule, Simon
    LANCET, 2016, 387 (10020): : 770 - 778
  • [43] ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma.
    Wang, Michael
    Locke, Frederick Lundry
    Munoz, Javier
    Goy, Andre
    Holmes, Houston Eccleston
    Siddiqi, Tanya
    Flinn, Ian
    McSweeney, Peter A.
    Reagan, Patrick Michael
    Hill, Brian Thomas
    Jacobson, Caron A.
    Rizzieri, David A.
    Heffner, Leonard T.
    Jaglowski, Samantha Mary
    Miklos, David Bernard
    Shaughnessy, Paul
    Unabia, Sherry
    Rossi, John M.
    Jiang, Yizhou
    Jain, Rajul K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    Witzig, TE
    Geyer, SM
    Ghobrial, I
    Inwards, DJ
    Fonseca, R
    Kurtin, P
    Ansell, SM
    Luyun, R
    Flynn, PJ
    Morton, RF
    Dakhil, SR
    Gross, H
    Kaufmann, SH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5347 - 5356
  • [45] Efficacy and safety of zanubrutinib in patients with relapsed or refractory mantle cell lymphoma: a systematic review
    Santoso, A. Febrian
    Margouw, R. Relia
    Maulidia, S. Azrianindita
    Kurniawan, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1341 - S1341
  • [46] Validation of the Functional Assessment of Cancer Therapy - Lymphoma (FACT-LYM) in Patients with Relapsed/Refractory Mantle Cell Lymphoma.
    Carter, Gebra Cuyun
    Liepa, Astra M.
    Zimmermann, Anna Hayden
    Morschhauser, Franck
    BLOOD, 2008, 112 (11) : 828 - 828
  • [47] Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial
    Freeman, Ciara L.
    Pararajalingam, Prasath
    Jin, Ling
    Balasubramanian, Sriram
    Jiang, Aixiang
    Xu, Wendan
    Grau, Michael
    Zapukhlyak, Myroslav
    Boyle, Merrill
    Hodkinson, Brendan
    Schaffer, Michael
    Enny, Christopher
    Deshpande, Sanjay
    Sun, Steven
    Vermeulen, Jessica
    Morin, Ryan D.
    Scott, David W.
    Lenz, Georg
    LEUKEMIA, 2022, 36 (10) : 2479 - 2487
  • [48] High dose chemotherapy and autologous hematopoietic progenitor cell support in patients with refractory or relapsed lymphoma.
    Keohan, ML
    Papadopoulos, KP
    Vahdat, LH
    Savage, DS
    Garrett, TJ
    Antman, KH
    Hesdorffer, CS
    BLOOD, 1997, 90 (10) : 4562 - 4562
  • [49] Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial
    Ciara L. Freeman
    Prasath Pararajalingam
    Ling Jin
    Sriram Balasubramanian
    Aixiang Jiang
    Wendan Xu
    Michael Grau
    Myroslav Zapukhlyak
    Merrill Boyle
    Brendan Hodkinson
    Michael Schaffer
    Christopher Enny
    Sanjay Deshpande
    Steven Sun
    Jessica Vermeulen
    Ryan D. Morin
    David W. Scott
    Georg Lenz
    Leukemia, 2022, 36 : 2479 - 2487
  • [50] GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Phillips, Tycel J.
    Matasar, Matthew
    Eyre, Toby A.
    Gine, Eva
    De L'Etang, Audrey Filezac
    Byrne, Ben
    Lundberg, Linda
    Padovani, Alejandra
    Boetsch, Christophe
    Bottos, Alessia
    Qayum, Naseer
    BLOOD, 2023, 142
12345